Trials / Unknown
UnknownNCT04994080
A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism
A Multi-center, Randomized, Double-blind, Parallel Grouping, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Paricalcitol Soft Capsules in the Treatment of Secondary Hyperparathyroidism in Subjects With Stage 3 and Stage 4 Chronic Kidney Disease
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, and safety of Paricalcitol for secondary hyperparathyroidism with stage 3 and stage 4 chronic kidney disease in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paricalcitol | Paricalcitol QD Treatment |
| DRUG | Placebo | Placebo QD or TIW |
Timeline
- Start date
- 2022-02-01
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
- First posted
- 2021-08-06
- Last updated
- 2022-02-10
Source: ClinicalTrials.gov record NCT04994080. Inclusion in this directory is not an endorsement.